Cholera Vaccine
Cholera (Vibrio cholerae)
Cholera is a severe diarrheal disease caused by Vibrio cholerae. Without treatment, the profuse watery diarrhea ('rice water stools') can cause fatal dehydration within hours. In outbreak settings — particularly in displaced populations, after natural disasters, or in areas lacking clean water — cholera can spread explosively. Global burden: 1.3–4 million cases and 21,000–143,000 deaths annually.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Cholera is a severe diarrheal disease caused by Vibrio cholerae. Without treatment, the profuse watery diarrhea ('rice water stools') can cause fatal dehydration within hours. In outbreak settings — particularly in displaced populations, after natural disasters, or in areas lacking clean water — cholera can spread explosively. Global burden: 1.3–4 million cases and 21,000–143,000 deaths annually.
Severe cholera causes extreme dehydration, muscle cramps, sunken eyes, and circulatory collapse. Death can occur within 2–12 hours without rehydration. Survivors typically recover fully with adequate treatment (oral rehydration salts, IV fluids). The primary burden is in contexts where healthcare access is limited, making early vaccination and water sanitation the critical interventions.
🛡️ Vaccine Effectiveness
Protection wanes over 2–3 years. In endemic settings, Shanchol/Euvichol provides ~65% protection for 5 years. Vaxchora (single dose, travelers) provides ~90% protection for the first 3 months but wanes significantly by 3 years. Boosters are recommended for ongoing risk.
Vaccinated individuals can contract cholera but typically have milder illness and are less likely to develop severe dehydrating disease. Vaccination also reduces environmental shedding, providing community-level protection.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Vaxchora: single oral dose, minimum 10 days before travel. Dukoral: 2 doses 1–6 weeks apart. Shanchol: 2 doses 14 days apart (preferred in endemic/outbreak settings). Booster at 2 years for ongoing risk. Not recommended for routine US childhood immunization — targeted to travelers and outbreak response.
⚖️ Benefits vs. Considerations
✓ Benefits
- Highly effective against severe disease and death in outbreak settings
- WHO pre-qualified oral vaccines are inexpensive and can be deployed in mass campaigns
- Single-dose option (Vaxchora) is highly convenient for travelers
- Proven to reduce outbreak intensity when deployed proactively in high-risk communities
- Excellent safety profile — primarily mild GI side effects
↕ Considerations
- Low relevance for most US residents not traveling to endemic areas
- Protection wanes: Vaxchora provides strong short-term protection but declines over 2–3 years
- Oral vaccine must be taken correctly (empty stomach, no food for 1 hour after)
- Not protective against all cholera strains (primarily O1 serogroup; O139 not covered)
- Access and cold-chain requirements limit deployment in the most resource-limited settings
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Some global health experts argue that oral cholera vaccine (OCV) campaigns divert resources from water and sanitation infrastructure, which is the only sustainable long-term solution (Bhattacharya & Bhattacharya, 2021). The WHO acknowledges OCV as a complement to, not substitute for, WASH improvements.
- The Vaxchora approval for travelers (single dose) used immunogenicity as a surrogate endpoint rather than direct efficacy data from travelers — some researchers argue the evidence base for traveler protection is weaker than for endemic populations.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Optimal single-dose vs. two-dose strategy in outbreak settings — single dose campaigns are more logistically feasible but may provide shorter protection
- Effectiveness of cholera vaccines in severely immunocompromised individuals
- Whether mass vaccination alone can interrupt outbreaks without concurrent WASH (water, sanitation, hygiene) improvements
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.